Page 98 - 《中国药房》2025年12期

186-190. valve replacement[J]. Asian Cardiovasc Thorac Ann，
[ 5 ] US Food and Drug Administration. Rivaroxaban side ef‐ 2020，28（9）：601-603.
fects[EB/OL].（2024-01-13）[2024-07-15]. https：//www.drugs. [18] XIONG H，LIU T，XIAO J P，et al. Warfarin-induced
com/sfx/rivaroxaban-side-effects.html#refs. Stevens-Johnson syndrome with severe liver injury[J]. J
[ 6 ] DUONG T A，VALEYRIE-ALLANORE L，WOLKENSTEIN Int Med Res，2021，49（7）：3000605211033196.
P，et al. Severe cutaneous adverse reactions to drugs[J]. [19] KLEY C，MURER C，MAUL J T，et al. Rapid involution
Lancet，2017，390（10106）：1996-2011. of pustules during topical steroid treatment of acute gene-
[ 7 ] JACOBSEN A，OLABI B，LANGLEY A，et al. Systemic ralized exanthematous pustulosis[J]. Case Rep Dermatol，
interventions for treatment of Stevens-Johnson syndrome 2017，9（1）：135-139.
（SJS），toxic epidermal necrolysis（TEN），and SJS/TEN [20] SCHROM K，PACIFICO A，CONIC R R Z，et al.
overlap syndrome[J]. Cochrane Database Syst Rev，2022， Dabigatran-associated acute generalized exanthematous
3（3）：CD013130. pustulosis（AGEP）in a psoriatic patient undergoing ixeki‐
[ 8 ] SASSOLAS B，HADDAD C，MOCKENHAUPT M，et al. zumab and its pathogenetic mechanism[J]. Dermatol Ther，
ALDEN，an algorithm for assessment of drug causality in 2019，32（5）：e13018.
Stevens-Johnson syndrome and toxic epidermal necroly‐ [21] LI D X，GOU J H，ZHU J，et al. Severe cutaneous adverse
sis：comparison with case-control analysis[J]. Clin Phar‐ reactions to drugs：a real-world pharmacovigilance study
macol Ther，2010，88（1）：60-68. using the FDA Adverse Event Reporting System database
[ 9 ] NARANJO C A，BUSTO U，SELLERS E M，et al. A [J]. Front Pharmacol，2023，14：1117391.
method for estimating the probability of adverse drug reac‐ [22] 中华医学会皮肤性病学分会药物不良反应研究中心 .
tions[J]. Clin Pharmacol Ther，1981，30（2）：239-245. Stevens-Johnson 综合征/中毒性表皮坏死松解症诊疗专
[10] BARRETT P，VUPPALANCHI R，MASUOKA H，et al. 家共识[J]. 中华皮肤科杂志，2021，54（5）：376-381.
Severe drug-induced skin and liver injury from rivaroxa‐ [23] UM S J，LEE S K，KIM Y H，et al. Clinical features of
ban[J]. Dig Dis Sci，2015，60（6）：1856-1858. drug-induced hypersensitivity syndrome in 38 patients[J].
[11] RADU C，BARNIG C，DE BLAY F. Rivaroxaban- J Investig Allergol Clin Immunol，2010，20（7）：556-562.
induced drug reaction with eosinophilia and systemic [24] CARLI G，FARSI A，CHIARINI F，et al. Hypersensitivity
symptoms[J]. J Investig Allergol Clin Immunol，2016，26 reactions to non-vitamin K oral anticoagulants： a review
（2）：124-126. of literature and diagnostic work-up proposal[J]. Eur Ann
[12] MENTEŞOĞLU D，GÜNAYDıN S D，ERSOY-EVANS Allergy Clin Immunol，2019，51（1）：7-14.
S. Drug reaction with eosinophilia and systemic symp‐ [25] CREADORE A，DESAI S，ALLOO A，et al. Clinical cha-
toms syndrome induced by apixaban[J]. Dermatol Ther， racteristics，disease course，and outcomes of patients with
2020，33（4）：e13719. acute generalized exanthematous pustulosis in the US[J].
[13] FERNANDO S L，LI J，TOON C W，et al. Acute genera- JAMA Dermatol，2022，158（2）：176-183.
lized exanthematous pustulosis to a novel oral anticoagu‐ [26] SHIOHARA T，MIZUKAWA Y. Drug-induced hypersensi‐
lant（apixaban）[J]. Ann Allergy Asthma Immunol，2021， tivity syndrome（DiHS）/drug reaction with eosinophilia
127（5）：588-589. and systemic symptoms（DRESS）：an update in 2019[J].
[14] NASH E，KENCH J，WATSON G，et al. A case of drug re‐ Allergol Int，2019，68（3）：301-308.
action with eosinophilia and systemic symptoms（DRESS） [27] HOTZ C，VALEYRIE-ALLANORE L，HADDAD C，
due to rivaroxaban[J]. Pathology，2023，55（7）：1022-1024. et al. Systemic involvement of acute generalized exanthe-
[15] TSOUMPRIS A，TZIMAS T，GKABRELAS K，et al. Iron matous pustulosis：a retrospective study on 58 patients[J].
complex，dabigatran and toxic epidermal necrolysis syn‐ Br J Dermatol，2013，169（6）：1223-1232.
drome：a case-report[J]. J Clin Pharm Ther，2013，38（2）： [28] CORTELLINI G，ROSSI F，LIPPOLIS D，et al. Delayed
177-178. hypersensitivity to new oral anticoagulants：demonstration
[16] KASAHARA K，GOTOH Y，KUROYANAGI Y，et al. of cross reactivity for the drug category and definition of
Warfarin-induced toxic epidermal necrolysis in combina‐ non-irritant concentrations for patch tests[J]. Eur Ann Al‐
tion therapy of Henoch-Schönlein purpura nephritis：a lergy Clin Immunol，2019，51（1）：38-40.
case report[J]. BMC Nephrol，2017，18（1）：237. （收稿日期：2024-12-24 修回日期：2025-04-29）
[17] KURODA T，YOKOYAMA Y，YAMADA M，et al. （编辑：陈 宏）
Warfarin-induced toxic epidermal necrolysis after mitral

· 1504 · China Pharmacy 2025 Vol. 36 No. 12 中国药房 2025年第36卷第12期